Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms

Clinical Pharmacology and Therapeutics
Ingrid OrdásWilliam J Sandborn

Abstract

Crohn's disease and ulcerative colitis are chronic inflammatory disorders resulting from immune dysregulation. Patients who fail conventional medical therapy require biological treatment with monoclonal antibodies (mAbs). Although mAbs are highly effective for induction and maintenance of clinical remission, not all patients respond, and a high proportion of patients lose response over time. One factor associated with loss of response is immunogenicity, whereby the production of antidrug antibodies accelerates mAb clearance. However, other factors related to patient and disease characteristics also influence the pharmacokinetics of mAbs. These factors include gender, body size, concomitant use of immunosuppressive agents, disease type, serum albumin concentration, and the degree of systemic inflammation. Because it is important to maintain clinically effective concentrations to provide optimal clinical response and drug exposure is affected by patient factors, a better understanding of the pharmacology of mAbs will ultimately result in better patient care.

References

May 25, 1973·Science·G M Edelman
Apr 1, 1970·The Journal of Clinical Investigation·A MorellT A Waldmann
May 6, 1999·The New England Journal of Medicine·D H PresentS J van Deventer
Feb 24, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·X ZhuR S Blumberg
Jun 6, 2002·Lancet·Stephen B HanauerUNKNOWN ACCENT I Study Group
Sep 5, 2002·British Journal of Clinical Pharmacology·Lewis B Sheiner
Jan 3, 2003·The New England Journal of Medicine·Subrata GhoshUNKNOWN Natalizumab Pan-European Study Group
Feb 14, 2003·The New England Journal of Medicine·Filip BaertPaul Rutgeerts
Sep 26, 1964·Nature·F W BRAMBELLI G MORRIS
Apr 15, 2004·Immunology Letters·Joël F G Cohen-SolalCatherine Sautès-Fridman
Jun 30, 2004·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Stephen B HanauerPaul Rutgeerts
Sep 25, 2004·Journal of Pharmaceutical Sciences·Evelyn D LoboJoseph P Balthasar
Apr 27, 2005·Seminars in Arthritis and Rheumatism·Ivan Nestorov
Sep 7, 2005·Gastroenterology·Stefan SchreiberUNKNOWN CDP870 Crohn's Disease Study Group
Sep 29, 2005·Expert Opinion on Biological Therapy·David Ternant, Gilles Paintaud
Dec 13, 2005·The New England Journal of Medicine·Paul RutgeertsJean Frédéric Colombel
Feb 16, 2006·Drug Discovery Today·Mohammad A TabriziLorin K Roskos
Feb 17, 2006·Gut·S P L TravisUNKNOWN European Crohn's and Colitis Organisation
Aug 26, 2006·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Elana A MaserGordon R Greenberg
Sep 8, 2006·Gut·Laurent Peyrin-BirouletPierre Desreumaux
Jul 20, 2007·The New England Journal of Medicine·William J SandbornUNKNOWN PRECISE 1 Study Investigators
Jul 20, 2007·The New England Journal of Medicine·Stefan SchreiberUNKNOWN PRECISE 2 Study Investigators
Jul 27, 2007·Nature·R J Xavier, D K Podolsky
Jul 28, 2007·Clinical Pharmacokinetics·Ulrich KlotzMatthias Schwab
Jun 14, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Laurent Peyrin-BirouletJean-Frédéric Colombel
Jul 22, 2008·Therapeutic Drug Monitoring·David TernantGilles Paintaud
Aug 19, 2008·Gastroenterology·William J SandbornUNKNOWN Ustekinumab Crohn's Disease Study Group
Sep 12, 2008·Clinical Pharmacology and Therapeutics·W WangJ P Balthasar
Sep 19, 2008·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·Jennifer JonesWilliam J Sandborn

❮ Previous
Next ❯

Citations

Aug 24, 2013·The New England Journal of Medicine·Ole Haagen Nielsen, Mark Andrew Ainsworth
Feb 6, 2013·Proceedings of the National Academy of Sciences of the United States of America·Brendan GongolJohn Y-J Shyy
Aug 21, 2013·PloS One·Guillaume NugueLaurent Pelletier
Jan 15, 2014·World Journal of Gastroenterology : WJG·Jannie PedersenOle Haagen Nielsen
Dec 19, 2013·Nature Reviews. Gastroenterology & Hepatology·Christina Y Ha, Seymour Katz
Aug 2, 2013·Immunotherapy·Reena Khanna, Brian G Feagan
Apr 24, 2014·Mediators of Inflammation·Romain Altwegg, Thierry Vincent
Dec 19, 2013·Nature Reviews. Gastroenterology & Hepatology·Mark E Gerich, Dermot P B McGovern
Jun 11, 2014·The American Journal of Gastroenterology·Xavier RoblinS Paul
Jul 6, 2014·DNA Research : an International Journal for Rapid Publication of Reports on Genes and Genomes·Mette BoydAlbin Sandelin
Apr 14, 2015·Scandinavian Journal of Gastroenterology·Daniël R HoekmanAngelika Kindermann
Oct 31, 2015·International Journal of Molecular Sciences·Jonathan K Dozier, Mark D Distefano
Nov 13, 2015·Expert Opinion on Drug Safety·Itishree Trivedi, Stephen B Hanauer
May 8, 2015·Expert Opinion on Biological Therapy·Carla FeliceAlessandro Armuzzi
Nov 12, 2013·Expert Opinion on Biological Therapy·Jeff Chang, Rupert W L Leong
Feb 14, 2016·Journal of Crohn's & Colitis·Alessandro Armuzzi, Simon Travis
Jun 28, 2015·Journal of Crohn's & Colitis·Sarah O'DonnellMark S Silverberg
Aug 3, 2016·The American Journal of Gastroenterology·Thomas BillietSeverine Vermeire
Mar 30, 2016·Journal of Crohn's & Colitis·Konstantinos PapamichaelSeverine Vermeire
Nov 1, 2016·Scandinavian Journal of Gastroenterology·Ashley BondSreedhar Subramanian
Dec 7, 2016·Expert Opinion on Drug Safety·Nikola Mitrev, Rupert W Leong
Feb 9, 2017·The Annals of Pharmacotherapy·James G StevensonLesley G Shane
May 4, 2017·The New England Journal of Medicine·William J SandbornUNKNOWN OCTAVE Induction 1, OCTAVE Induction 2, and OCTAVE Sustain Investigators
May 20, 2017·Clinical Pharmacokinetics·Maria RosarioIrving Fox
May 26, 2017·Wiley Interdisciplinary Reviews. Nanomedicine and Nanobiotechnology·Husain AttarwalaMansoor Amiji
Nov 20, 2015·Journal of Pediatric Gastroenterology and Nutrition·Jason M ShapiroNeal S LeLeiko
Jun 21, 2014·The AAPS Journal·Diane R MouldJessica Wojciechowski
Jan 7, 2017·Journal of Controlled Release : Official Journal of the Controlled Release Society·Hongliang HeHu Yang

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association
Ingrid OrdásWilliam J Sandborn
Inflammatory Bowel Diseases
Jean-Frédéric ColombelAnne M Robinson
Current Treatment Options in Gastroenterology
Reena Khanna, Brian G Feagan
© 2022 Meta ULC. All rights reserved